nice looking set up on this bio play. watching for a move over 5 $XBI $CPRX
Dates in the future with the highest probability for price direction reversals
Firdapse Spinal Muscular Atrophy (SMA) Type 3 **** Phase 2 data due 1H 2020 Firdapse MuSK-antibody positive myasthenia gravis (MuSK-MG) **** Phase 3 data due 1H 2020 Short Float = 13.23% Broke out of triangle, looking for a small pullback to the cloud / support line, have a stop under suport line at 4.20 and Target at 7.50 for at possible 70% upside...
Buyers have come into market breakout the upper trend line backed by volume to form a bullish wedge breakout
Buyers have broken upper trend line with increase volume forming a bullish wedge trend line breakout
I forgot what this strategy was called. Please let me know in the comment.
Looks like a decent setup, but possibly early and unpredictable. Dec or Jan calls are cheap enough for a tiny position.
Buy and sell opportunity: wait for a bullish and bearish reversal in buy and sell zones respectively. Trend analysis: Monthly - up Weekly - up Daily - down (correction) Hourly - down Long-term opportunity: buy Short-term opportunity: sell
The setup on the weekly chart looks quite good with price now reaching an area of supportive confluence. I anticipate price support is found on the trendline and fibs where high R-multiple long setups can be constructed. If we decline further I am watching $4.50 and $4.31 (0.618 fib) for a strong bounce. The news this week is immaterial to CPRX's valuation,...
Now that the bullish trend broke after failed CMS trials, target the next support region between Target $3-3.50
With a confluence of strong fundamentals and technical setup CPRX should see $8.60 as a first medium term price target, a 50% price increase from closing price on 10/25/19. Long term CPRX has the potential to go materially higher than first price target based on fundamentals and sell-side consensus.
weekly data, regression analysis hit upper band, major candle stick wick.. blow that candle out! due to offering 8 million new shares diluting value. FIB can retrace back to $2.5 if we arent careful, already did a month ago . On the medical side the product does have staying power, just a matter of selling it, expensive price tag though. 1st in class As per...
Uptrend should continue.